Posters

Effectiveness of infliximab in Behçet's disease with previous development of anti-infliximab antibodies

Poster Details

First Author: M.Gomez-Resa SPAIN

Co Author(s):    J. Olea   P. Rocha Cabrera   J. Aragon                       

Abstract Details



Purpose:

To describe a case of acute unilateral optic neuritis in a patient diagnosed with Behçet's disease.

Setting:

Tertiary care hospital.

Methods:

Case report.

Results:

We present a case of a 46-year-old woman in maintenance treatment with prednisone 5mg/daily and methotrexate 17.5mg/weekly due to Behçet's disease with ocular involvement with repeated outbreaks of posterior uveitis in her left eye, who comes to the emergency room because of a sudden loss of vision acuity in her right eye. BCVA was CF in her RE (previous 1). In the funduscopy there was an optic disc edema in her RE without other accompanying signs. We started treatment with prednisone 90mg/daily, methotrexate17.5mg/weekly and intravenous infliximab 5mg/kg/biweekly, despite the antecedent of development of anti-infliximab antibodies with its previous use. BCVA improved to 20/63 three hours after the first infusion of infliximab; until 20/25 a week later; and finally until 20/20 a month later, with complete resolution optic disc edema. Treatment with infliximab was stopped because anti-infliximab antibodies were developed (265 AU / ml). The remission of ocular involvement was maintained during two years of follow-up with low dose prednisone.

Conclusions:

Infliximab is effective in the treatment of recurrences of Behçet's disease with ocular involvement despite the antecedent of development of anti-infliximab antibodies.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy